Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>United Therapeutics Corporation (United Therapeutics) reported a strong performance in the first quarter of 2025 with record revenue of $794 million, marking a 17% increase compared to the same period in 2024.</li><li>The company's commercial success continues to be driven by its key products: Tyvaso, Orenitram, Remodulin, and Unituxin, all of which have demonstrated consistent growth due to robust patient demand and increased prescriber engagement.</li><li>Tyvaso products, both the DPI (dry powder inhaler) and nebulizer forms, have shown significant market penetration, effectively contributing to the company's revenue and hinting at an optimistic future outlook.</li></ul>

United Therapeutics Corporation (United Therapeutics) reported a strong performance in the first quarter of 2025 with record revenue of $794 million, marking a 17% increase compared to the same period in 2024.The company's commercial success continues to be driven by its key products: Tyvaso, Orenitram, Remodulin, and Unituxin, all of which have demonstrated consistent growth due to robust patient demand and increased prescriber engagement.Tyvaso products, both the DPI (dry powder inhaler) and nebulizer forms, have shown significant market penetration, effectively contributing to the company's revenue and hinting at an optimistic future outlook.

United Therapeutics: Expansion into Organ Xenotransplantation to Position Itself As A Pioneer In This Emerging Domain!